While the vast majority of prostate tumours remain asymptomatic [1, 55], following surgery or radiation therapy approximately one third of patients with localised PCa experience disease relapse, in what is diagnostically termed “biochemical recurrence (BCR)” or PSA failure [3]. This evidence concerns the gene PROS1 and prostate neoplasm.